Your browser doesn't support javascript.
loading
Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis-Multicenter SVG PCI PROTECTA Study.
Wanha, Wojciech; Mielczarek, Maksymilian; Gilis-Malinowska, Natasza; Roleder, Tomasz; Milewski, Marek; Ladzinski, Szymon; Ciecwierz, Dariusz; Gasior, Pawel; Pawlowski, Tomasz; Januszek, Rafal; Kowalówka, Adam; Kolodziejczak, Michalina; Bartus, Stanislaw; Gruchala, Marcin; Smolka, Grzegorz; Navarese, Eliano Pio; Dudek, Dariusz; Ochala, Andrzej; Kedhi, Elvin; Jaguszewski, Milosz; Wojakowski, Wojciech.
Afiliación
  • Wanha W; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Mielczarek M; First Department of Cardiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
  • Gilis-Malinowska N; First Department of Cardiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
  • Roleder T; Regional Specialist Hospital, Research, and Development Center, 51-124 Wroclaw, Poland.
  • Milewski M; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Ladzinski S; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Ciecwierz D; First Department of Cardiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
  • Gasior P; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Pawlowski T; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Januszek R; Second Department of Cardiology, Jagiellonian University Medical College, 31-501 Krakow, Poland.
  • Kowalówka A; Department of Cardiac Surgery, Medical University of Silesia, 40-635 Katowice, Poland.
  • Kolodziejczak M; Department of Anaesthesiology and Intensive Care, Antoni Jurasz University Hospital No. 1, 85-094 Bydgoszcz, Poland.
  • Bartus S; SIRIO MEDICINE research network, 85-094 Bydgoszcz, Poland.
  • Gruchala M; Second Department of Cardiology, Jagiellonian University Medical College, 31-501 Krakow, Poland.
  • Smolka G; First Department of Cardiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
  • Navarese EP; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
  • Dudek D; SIRIO MEDICINE research network, 85-094 Bydgoszcz, Poland.
  • Ochala A; Cardiovascular Institute, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland.
  • Kedhi E; Department of Cardiovascular Medicine, University of Alberta, Edmonton, AB 13-103, Canada.
  • Jaguszewski M; Second Department of Cardiology, Jagiellonian University Medical College, 31-501 Krakow, Poland.
  • Wojakowski W; Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland.
J Clin Med ; 9(4)2020 Apr 22.
Article en En | MEDLINE | ID: mdl-32331299
Background: Evidence concerning the efficacy of the embolic protection devices (EPDs) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI) is sparse. The study was designed to compare major cardiovascular events of all-comer population of SVG PCI with and without EPDs at one year of follow-up. Methods and results: A multi-center registry comparing PCI with and without EPDs in consecutive patients undergoing PCI of SVG. The group comprised 792 patients, among which 266 (33.6%) had myocardial infarction (MI). The primary composite endpoint was major adverse cardiac and cerebrovascular event (MACCE) defined as death, MI, target vessel revascularization (TVR), and stroke assessed at one year. After propensity score analysis, there were no differences in MACCE (21.9% vs. 23.9%; HR 0.91, 95% CI 0.57-1.45, p = 0.681, respectively) nor in secondary endpoints of death, MI, TVR, target lesion revascularization (TLR) and stroke at one year in EPDs PCI group vs. no-EPDs PCI group. Similarly, there were no differences between groups in the study endpoints at 30 days follow-up. Conclusions: There were no clinical benefit for routine use of EPDs during SVG PCI in short and long-term follow-up. Further studies are warranted to explore the effect of individual types of EPDs on clinical outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Clin Med Año: 2020 Tipo del documento: Article País de afiliación: Polonia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Clin Med Año: 2020 Tipo del documento: Article País de afiliación: Polonia